News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 672 results
June 2016
-
Media ReleaseLargest global psoriasis survey shows 85% of U.S. respondents faced social stigma like discrimination and humiliation because of their skin- Global survey, including more than 1,400 U.S. moderate-to-severe psoriasis patients, is the first to look at perceptions of clear skin1- Despite the significant impact of living with the disease,…
-
Media ReleaseLargest global psoriasis survey shows 85% of U.S. respondents faced social stigma like discrimination and humiliation because of their skin
-
Media ReleaseTimely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA CardiologyFindings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors)(1)Cardiology experts highlight risk of…
-
Media ReleaseTimely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
-
Media ReleaseNovartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS- Data demonstrate at 12 months, 81% of patients started on fingolimod stay on therapy vs. 29% started on injectable disease-modifying therapies (iDMTs)(1)- Injectable disease-modifying therapies are…
-
Media ReleaseNovartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS
May 2016
-
Media ReleaseMedia Statement: Leading US cardiology societies strongly recommend Entresto® as a new standard of care treatment in an earlier-than-expected joint update of clinical practice guidelines for heart failureThree leading US cardiology societies have jointly issued a clinical practice guideline update that has redefined standard of care treatment for heart failure and given Entresto® a strong Class I…
-
Media ReleaseMedia Statement: Leading US cardiology societies strongly recommend Entresto® as a new standard of care treatment in an earlier-than-expected joint update of clinical practice guidelines for heart failure
-
Media ReleaseMedia Statement: FortiHFy Global Clinical Program for Entresto®Novartis has established FortiHFy, the largest global clinical program in the heart failure disease area, comprising over 40 active or planned clinical studies designed to generate an array of…
-
Media ReleaseMedia Statement: FortiHFy Global Clinical Program for Entresto®
April 2016
-
Media ReleaseNovartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes-- Subject to approvals, Ilaris® (canakinumab) will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF-- Designations support…
-
Media ReleaseNovartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes
Pagination
- ‹ Previous page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- …
- 56
- › Next page